The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically ...

AstraZeneca (LSE:AZN) announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia ...

Gefurulimab is a dual-binding nanobody designed to bind to the C5 protein in the terminal complement cascade and prevent the overactivation of the body’s immune system.

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of ...

"gMG race hots up as AstraZeneca’s star candidate meets Phase III targets" was originally created and published by Clinical ...

Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice ...

The phase 3 trial randomized 260 people with anti-acetylcholine receptor antibody-positive gMG to take gefurulimab or placebo. After 26 weeks, people on gefurulimab performed significantly better on a ...

With treatment, myasthenia gravis can generally be controlled. In fact, about 50 percent of people who have their thymus gland removed may experience long-lasting, complete remission of myasthenia ...